Subtype
Esophageal Carcinoma
CI-CAN-00002609ESCAExplore in graph →
307 active trials4 approved drugs11 evidence items
- NCIt
- C3513
- DOID
- 1107
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00002609ESCAExplore in graph →
Clinical trials
807 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (62)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) | suspended | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | suspended | Phase 4 | 36 | University of ChicagoOTHER | 1 | Mar 30, 2026 |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. | suspended | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
Data updated 22 days agoSource updated May 4, 2026source: clinicaltrials